ABSTRACT
ObjectiveTo investigate the specific anti-SARS-CoV-2 antibody in adults and above after initial vaccination with inactivated COVID-19 vaccine， and determine the influencing factors. MethodsIn this study， residents aged 18 and above who had completed two doses of inactivated COVID-19 vaccine in Deqing County， Huzhou City， Zhejiang Province were included. Information such as gender， age， type of vaccine and vaccination time were collected， and serum specimens were sampled. Anti-SARS-CoV-2 receptor binding domain （RBD） antibody was quantitatively examined by enzyma-linked immunosorbent assay （ELISA） and influencing factors were determined. ResultsThe median concentration of anti-SARS-CoV-2 IgG antibody in the residents vaccinated with an inactivated booster vaccine was higher than that in those vaccinated with only two doses of COVID-19 vaccine or single dose （P<0.05）. The median concentration of IgG antibody in males was 9.73 （4.01‒23.70） RU‧mL-1， lower than 17.76 （7.07‒49.23） RU‧mL-1 in females （P<0.05）. The median concentration in the residents vaccinated with BBIBP-CorV （Sinopharm） was 6.53 （0.97‒13.69） RU‧mL-1， which was lower than that in those vaccinated with CoronaVac （Sinovac） that was 17.29 （8.54‒43.73） RU‧mL-1 （P<0.05）. The median concentration in those with BBIBP-CorV was also lower than 12 （5.45‒40.06） RU‧mL-1 in those with heterologous booster vaccine （P<0.05）. The median concentration was 9.73 （3.83‒23.63） RU‧mL-1 in the residents with an interval of more than 6 months from the second dose， which was lower than 14.66 （6.36‒35.98） RU‧mL-1 in those with an interval of 3‒6 months （P<0.05）. Moreover， immune effect was better in females （χ²=16.464， P<0.05）， 18‒45 years（χ²=7.158， P<0.05）， and those vaccinated with CornaVac （χ²=49.637， P<0.05）， while decreased in those with an interval of more than 6 months from the second dose （χ²=8.447， P<0.05）. ConclusionGender， age， and type of vaccine may affect the effect of immunization. The COVID-19 vaccination shows an acceptable immunogenicity in adults； however， it declines in 6 months after vaccination. It warrants strengthening the booster vaccination to maintain the immune response.
ABSTRACT
We expressed B cell epitopes of dengue virus envelope protein and NS1 protein in prokaryotic cells,and purified and evaluated for its serological activities.A recombinant multi-epitope chimeric gene named rE including eight B cell epitopes was connected by linker peptide (EAAAK)2 and cloned into prokaryotic expression vector pET-28a(+),and transformed into E.coli BL21(DE3) cells for expression under induction of IPTG.The expressed recombinant protein was purified with 6× His purification media,and identified by SDS-PAGE and Western blot,and its antigenicity was analyzed by using an indirect ELISA assay.The recombinant expression vector pET28a-rE was constructed and expressed in BL21 (DE3) successfully,but the recombinant proteins mainly appeared as inclusion bodies.The target protein was obtained with high purity through the purification of affinity chromatography.SDS-PAGE and Western blot analysis showed that the molecular weight of fusion protein was in the expected line.The established indirect ELISA has high accuracy.This recombinant peptide antigen expressed in E.coli has good potential for serum testing.